Inozyme Pharma Inc (NAS:INZY)
$ 5.73 0.27 (4.95%) Market Cap: 354.43 Mil Enterprise Value: 216.36 Mil PE Ratio: 0 PB Ratio: 2.98 GF Score: 40/100

Inozyme Pharma Inc Investor and Analyst Event (Virtual) Transcript

Feb 16, 2023 / 01:00PM GMT
Release Date Price: $2.7 (+21.62%)
Stefan Riley
Inozyme Pharma, Inc. - IR

Good morning and thank you for joining us for the Inozyme February 2023 virtual investor and analyst event. Today's remarks will be followed by a question-and-answer session with the management team and key opinion leaders, please dial in via telephone to participate.

Before we begin our formal remarks, I would like to point you to our forward-looking statements disclaimer.

I would now like to turn the event over to Axel Bolte, Co-Founder, President, and Chief Executive Officer of Inozyme Pharma.

Axel Bolte
Inozyme Pharma, Inc. - Co-Founder, President & CEO

Good morning, and welcome to our first investor and analyst event from our labs in Boston. Inozyme has made tremendous progress over the past year. We are developing a potential first-in-class therapy for ENPP1 Deficiency and ABCC6 Deficiency, two rare mineralization disorders, where patients suffer severely with up to 50% mortality and have no approved therapeutic options.

With INZ-701, we have a Phase 3-ready asset that has shown a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot